First-in-Human gene therapy injected into brain for Parkinson's

NCT ID NCT04127578

Summary

This is an early-stage study testing a new gene therapy called LY3884961 for people with moderate to severe Parkinson's disease who have a specific genetic mutation (GBA1). The therapy is delivered via a single injection into the fluid around the brain and spinal cord. The main goal is to check the treatment's safety and see how the body responds over a 5-year period, while also looking for early signs that it might help control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Esperanza Clinical, 25220 Hancock Avenue

    Murrieta, California, 92562, United States

  • Hadassah Medical Center, Hadassah Ein Kerem, Dept. of Neurology, P.O. Box 12000

    Jerusalem, 91120, Israel

  • Hospital of the University of Pennsylvania, 330 S. 9th Street

    Philadelphia, Pennsylvania, 19107-6103, United States

  • Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street

    New York, New York, 10065, United States

  • K2 Medical Research, 101 Southhall Lane, Suite 150

    Maitland, Florida, 32751-5669, United States

  • Mayo Clinic, 13400 E. Shea Boulevard

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic, 200 First Street SW

    Rochester, Minnesota, 55905, United States

  • Mount Sinai Beth Israel, 10 Union Square East, Suite 5H

    New York, New York, 10003, United States

  • Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor

    Chicago, Illinois, 60611, United States

  • PPD, 100 West Gore Street, Suite 202

    Orlando, Florida, 32806, United States

  • Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510

    Englewood, Colorado, 80113-2776, United States

  • Shaare Zedek Medical Center, 12 Shmuel Biet Street

    Jerusalem, 91031, Israel

  • Sheba Medical Center, Tel Hashomer

    Ramat Gan, 52621, Israel

  • Tel Aviv Sourasky Medical Center, 6 Weizmann St.

    Tel Aviv, 64239, Israel

  • Vanderbilt University Medical Center, 1500 21st Avenue South Suite 2600

    Nashville, Tennessee, 37212, United States

Conditions

Explore the condition pages connected to this study.